Product News

Porvair Sciences sets a new standard for labs with Microlute Protein Precipitation Plate

, 26 August 2020/in Product News /by 3wmedia

Incorporating a novel dual hydrophobically treated matrix filter, Microlute Protein Precipitation Plate from Porvair Sciences sets a new standard for labs looking to remove interfering proteins from serum, plasma or whole blood samples prior to analysis by Liquid Chromatography / Mass Spectrometry (LC/MS). Biological samples commonly contain proteins that interfere with downstream applications such as LC/MS analysis. Microlute Protein Precipitation Plates (PPP) use the CRASH method, in which protein is denatured with acetonitrile and the flocculant filtered out, allowing 96 samples to be processed in parallel. Based on the industry standard MicroLute format, but without the chromatographic sorbent, protein ‘crashes’ out of solution and precipitates directly in each well when acetonitrile is added, thus solving all common problems associated with the CRASH technique of protein cleanup. The novel dual frit, hydrophobically treated matrix used by the Microlute PPP means that there is no ‘wetting out’ and leakage of sample before the application of vacuum. Due to its ease of use, high performance and reliability the Microlute PPP is commonly used as the protein precipitation plate of choice in many major pharmaceutical companies worldwide. Established in 1992, Porvair Sciences is one of the largest global manufacturers of ultra-clean microplates and top-quality microplate equipment for life science, synthetic chemistry and many other applications.
Read more

Serum Amyloid A (SAA), CE-IVD marked, turbidimetric assay

, 26 August 2020/in Product News /by 3wmedia

TRIMERO has added to its catalogue a new Serum Amyloid A, CE-IVD marked, particle-enhanced turbidimetric immunoassay. Applications are available for the most popular clinical chemistry analysers, and for IMMAGE® nephelometers of Beckman Coulter. In order to ensure lot to lot traceability, the assay has been standardized to the Serum Amyloid A (SAA) 1^st International Standard (NIBSC code: 92/680) of the WHO (World Health Organization).

Other available assays for turbidimetry and nephelometry include:

KLoneus® Free Light Chains (FLC), IgD Immunoglobulins, Retinol Binding Protein (RBP) for serum and urine, Soluble Transferrin Receptor (sTfR), Hemopexin, Cystatin-C for serum and urine, A1-Microglobulin, B2-Microglobulin for serum and urine, Kappa and Lambda Light Chains for serum and urine, Complement C1q, Complement C5, Factor B (C3 Proactivator), C1 (Esterase) Inhibitor.

Ansh labs launches two new immunoassays for SARS-COV2

Ansh labs has launched two new immunoassays, SARS-CoV2 IgG and IgM ELISAs, to assist in the fight against the Covid-19 pandemic.
Ansh Labs is releasing these two kits for sale in the United States under the provisions outlined in Section D of Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. At the time of going to press, these tests were under review by the FDA for an Emergency Use Authorization.
IgM antibody is the first to be produced in response to viral proteins (antigens) and will be primarily detectable during the early onset of the disease. IgG antibodies are long-lasting and can persist in the bloodstream for many years after infection. This test has the advantage of detecting not only individuals with active infection (IgM), but also those who were previously exposed to the virus and may have subsequently developed immunity (IgG).
Testing for SARS-CoV2 antibodies can help in epidemiological surveillance about the spread of the virus and possible herd immunity. Ansh Labs’ SARS-CoV2 ELISAs are highly accurate with IgG ELISA offering 96% specificity and IgM ELISA offering 99% specificity.
For more information, visit: www.covid-diagnostics.com
Read more

Porvair Sciences expands range of black microplates

, 26 August 2020/in Product News /by 3wmedia

Porvair Sciences has expanded its range of high quality, black microplates that minimise sample degradation by exposure to light, even over long storage periods.
Available in a choice of 48-, 96- and 384-well formats – the black plates are precisely manufactured to applicable ANSI / SLAS dimensions ensuring complete compatibility with almost all readers and automated equipment. Manufactured from polypropylene, the range of black microplates offer excellent heat and solvent resistant qualities. Using only ultra-pure grade polymer means that each black plate has near zero leachates ensuring long-term sample integrity. The black plates are supplied RNase / DNase free meaning they can be used to store the most sensitive biological samples. To prevent evaporation, hydration of DMSO solutions and to completely eliminate light from samples – Porvair Sciences additionally offers a selection of Absorb Max light blocking sealing films that may be applied to the top of the black plates. A split backing and edge cut-outs make positioning and applying the sealing film quick and simple. The light-blocking and absorbing properties of Porvair Sciences black microplates, used in conjunction with Absorb Max sealing films, provides a perfect combination for protecting light-sensitive assays or samples during storage.
For more information, visit: www.microplates.com/solid-bottom
Read more

ELISA for urinary sCD163 measurement

, 26 August 2020/in Product News /by 3wmedia

Urinary soluble CD163 (sCD163) is a novel non-invasive marker of renal inflammation, and its determination supports early detection and monitoring of active glomerulonephritis (GN). Studies by experts in the field led by Prof. Mark Little (Trinity College, Dublin, Ireland) showed that significantly increased sCD163 levels in urine are present in up to 87% of patients with active ANCA-associated vasculitis (AAV) with renal involvement. In contrast, only slight increases are detected in AAV patients in remission, patients with acute kidney failure or sepsis, and patients with AAV without kidney involvement (O’Reilly et al. Am Soc Nephrol 27: 2906–2916, 2016). Furthermore, urinary sCD163 is elevated in patients with non-vasculitic forms of GN, especially in patients with lupus nephritis class IV (Endo et al. J Nephrol Dial Transplant. 31(12): 2023-2033, 2016). sCD163 is a macrophage activation marker. The sCD163 level in urine correlates directly with the kidney disease activity, reflecting the accumulation of CD163+ macrophages in the glomeruli in response to pro-inflammatory stimuli. The direct correlation with renal inflammation means that urinary sCD163 is superior in performance to standard urinary markers, which have limited value in identifying a renal relapse. Monitoring of urinary sCD163 values can help to predict renal flares before irreversible kidney damage occurs and might enable invasive kidney biopsies to be avoided. sCD163 can be measured quantitatively in urine samples using a new ELISA from EUROIMMUN. The detection is based on monoclonal anti-sCD163 antibodies. Values are determined by means of a simple cut-off-based interpretation using 6 calibrators. The EUROIMMUN sCD163 ELISA will soon be available as IVD CE-marked assay.

Horizon Discovery CHOSOURCE platform supports development of immunotherapy for autoimmune diseases

, 26 August 2020/in Product News /by 3wmedia

Horizon Discovery Group, a leader in the application of gene editing and gene modulation for cell line engineering, says its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s pharmaceutical-grade, stable Chinese Hamster Ovary (CHO) cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, enabling Immutep and Batavia Biosciences to reach an important milestone in the preclinical development of the compound.
Horizon’s gene-edited Glutamine Synthetase (GS) knockout CHO K1 cell line expression system, offered by Batavia Biosciences as part of its STEP®-mAb service, was used to generate a high yielding cell line for Immutep’s IMP761 product candidate, an agonist antibody targeting the immune checkpoint lymphocyte activation gene (LAG)-3. LAG-3 controls the signalling between specific immune cells, T cells and antigen presenting cells, which are responsible for the adaptive immune response, making it a promising focus for novel cancer therapies or for the treatment of autoimmune conditions, such as inflammatory bowel diseases, rheumatoid arthritis, and multiple sclerosis.
Horizon’s GS expression system facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins and is recognized in the industry and by regulators as suitable for high yield biomanufacturing. Its CHOSOURCE biomanufacturing platform helps companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible. The platform is versatile and suitable for a broad range of monoclonal antibody therapeutics, delivering higher-than-anticipated yields of less commonly used IgG4-based antibodies, such as IMP761.
Terry Pizzie, CEO, Horizon Discovery said: “We are dedicated to ensuring availability of key technologies that can improve affordability of medicines worldwide. Our CHOSOURCE biomanufacturing platform is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production and has already been utilized in multiple successful innovative new drug filings.”
The complete CHOSOURCE system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc.
• For more information, visit: https://horizondiscovery.com/navigation/cho-cells
Read more

Randox Reagents Webvertorial CLI November 2019 IMAGE

Randox diabetes testing portfolio

, 26 August 2020/in Product News /by 3wmedia

Type 2 diabetes mellitus (T2DM) now attains the status of global pandemic, spreading from developed to developing countries. The epidemiological trends indicate that the prevalence will continue to increase dramatically. The World Health Organization estimates diabetes to be the seventh global leading cause of death, accounting for 1.6 million deaths in 2016. Randox is committed to advancing diabetes testing, including the associated complications. Randox offers a comprehensive range of high quality reagents ranging from diabetes risk assessment, diagnosis and monitoring of diabetes, and monitoring of associated complications. The Randox diabetes portfolio covers the full spectrum of clinical biochemistry laboratory testing requirements including several superior performance and unique assays. Applications are available detailing instrument-specific settings for a wide range of clinical chemistry analysers. https://www.randox.com/diabetes-reagents/
Read more

Human Myosin Binding Protein-C3 ELISA

, 26 August 2020/in Product News /by 3wmedia

Cardiac MyBP-C may be more useful than the gold standard biomarker cardiac Troponin I. Blood levels of the current gold standard cardiac biomarkers are very low during the initial stages of myocardial infarction (MI), making early diagnosis difficult. Plasma levels of MyBPC3 are significantly elevated in MI patients. MyBPC3 levels increase from baseline at 3 hours after MI and peak at 6 hours. This is faster than for Cardiac Troponin I which is normally detected 6-12 hours after the onset of MI. Cardiac MyBPC (cMyBP-C, MyBPC3) is a 140 kDa structural protein that is present only in the heart. It is phosphorylated by several kinases. Phosphorylation of MyBPC3 regulates myocardial function and confers resistance to proteolysis, preserving cardiac function post-myocardial infarction. Dephosphorylation at Ser-273 and Ser-282 facilitates MyBPC3 degradation and release of a 40 kDa N-terminal fragment (C0C1f). This C0C1f fragment is pathogenic within cardiac tissue and it is released into the circulation. It was later established in vivo that the C0C1f fragment could cause cardiac dysfunction and heart failure. Importantly, it was shown that plasma MyBPC3 levels are significantly raised in humans with hypertrophic cardiomyopathy undergoing trans-coronary ablation of septal hypertrophy. The assay is validated for human serum and citrate plasma and shows excellent sensitivity (LOD 1.74 pg/ml).

BIOVENDOR
Read more

Porvair Sciences sets a new standard for labs with Microlute Protein Precipitation Plate

Serum Amyloid A (SAA), CE-IVD marked, turbidimetric assay

Ansh labs launches two new immunoassays for SARS-COV2

Porvair Sciences expands range of black microplates

ELISA for urinary sCD163 measurement

Horizon Discovery CHOSOURCE platform supports development of immunotherapy for autoimmune diseases

Randox diabetes testing portfolio

Human Myosin Binding Protein-C3 ELISA

Latest issue of Clinical laboratory

ESCMID

Medlab Middle East

ADLM

Free subscription

Get our e-alert